Kolorektale Lebermetastasen: Aktueller Stand der multimodalen Therapie
暂无分享,去创建一个
[1] J. Fahlke,et al. Palliative Chemotherapie beim kolorektalen Karzinom – Stand, Wertigkeit, Tendenzen , 2010, Zentralblatt fur Chirurgie.
[2] P. Colombo,et al. Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases? , 2010, Annals of surgery.
[3] F. Lévi,et al. Regenerative Nodular Hyperplasia of the Liver Related to Chemotherapy: Impact on Outcome of Liver Surgery for Colorectal Metastases , 2010, Annals of Surgical Oncology.
[4] M. Mottolese,et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial , 2010, British Journal of Cancer.
[5] M. Puhan,et al. Impact of Preoperative Bevacizumab on Complications After Resection of Colorectal Liver Metastases: Case-Matched Control Study , 2010, World Journal of Surgery.
[6] P. Wust,et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. , 2010, International journal of radiation oncology, biology, physics.
[7] S. Curley,et al. Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases , 2010, Annals of Surgical Oncology.
[8] P. Bachellier,et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[9] S. Curley,et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? , 2010, Journal of the American College of Surgeons.
[10] T. Helmberger,et al. Interventionelle Verfahren bei Lebermetastasen , 2010, Der Chirurg.
[11] J. Vauthey,et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] U. Neumann,et al. The surgical treatment of hepatic metastases in colorectal carcinoma. , 2010, Deutsches Arzteblatt international.
[13] S. Curley,et al. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. , 2010, Archives of surgery.
[14] E. Abdalla,et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin‐associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis , 2010, Histopathology.
[15] D. Seehofer,et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[16] R. J. Haas,et al. Impact of portal vein embolization on long‐term survival of patients with primarily unresectable colorectal liver metastases , 2010, The British journal of surgery.
[17] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[18] C. Bokemeyer,et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] V. Georgoulias,et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] O. Drognitz,et al. Zeitlicher Ablauf von Leber- und Darmresektion bei Patienten mit kolorektalem Karzinom und synchronen Lebermetastasen , 2009 .
[21] D. Sargent,et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] L. Schwartz,et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Mocellin,et al. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. , 2009, The Cochrane database of systematic reviews.
[24] U. Neumann,et al. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. , 2009, Surgery.
[25] M. Ychou,et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] T. Gruenberger,et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[27] V. Paradis,et al. Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab , 2009, Annals of Surgical Oncology.
[28] B. Nordlinger,et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. , 2009, Surgery.
[29] E. Vasile,et al. Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases , 2009, Annals of surgery.
[30] C. Bokemeyer,et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] H. Bismuth,et al. Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases , 2008, Annals of surgery.
[32] R. Labianca,et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Adam,et al. R1 Resection by Necessity for Colorectal Liver Metastases: Is It Still a Contraindication to Surgery? , 2008, Annals of surgery.
[34] J. Riemann1,et al. S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008 , 2008 .
[35] T. Seufferlein,et al. S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008 , 2008, Zeitschrift fur Gastroenterologie.
[36] I. B. Borel Rinkes,et al. RADIOFREQUENCY ABLATION (RFA) COMBINED WITH CHEMOTHERAPY FOR UNRESECTABLE COLORECTAL LIVER METASTASES (CRC LM): INTERIM RESULTS OF A RANDOMISED PHASE II STUDY OF THE EORTC-NCRI CCSG-ALM INTERGROUP 40004 (CLOCC) , 2008 .
[37] W. Scheithauer,et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Thomas Gruenberger,et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Thomas Gruenberger,et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.
[40] L. Schwartz,et al. Combined Portal Vein Embolization and Neoadjuvant Chemotherapy As a Treatment Strategy for Resectable Hepatic Colorectal Metastases , 2008, Annals of surgery.
[41] C. Sempoux,et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[42] M. Ducreux,et al. Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin , 2007, Annals of Surgical Oncology.
[43] W. Jochum,et al. Hepatic Steatosis Is a Risk Factor for Postoperative Complications After Major Hepatectomy: A Matched Case-Control Study , 2007, Annals of surgery.
[44] R. Parks,et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. , 2007, Journal of the American College of Surgeons.
[45] Daniel Azoulay,et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Catherine Julié,et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Morel,et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary , 2006, The British journal of surgery.
[48] R. Hutchins,et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. , 2006, The British journal of radiology.
[49] T. Pawlik,et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] V. Vilgrain,et al. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction , 2006, Journal of Gastrointestinal Surgery.
[51] B. Nordlinger,et al. Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases , 2006, Annals of surgery.
[52] C. Köhne,et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] M. Pocard,et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases , 2005, Journal of surgical oncology.
[54] F. Lévi,et al. Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.
[55] P. Bachellier,et al. A Two-Stage Hepatectomy Procedure Combined With Portal Vein Embolization to Achieve Curative Resection for Initially Unresectable Multiple and Bilobar Colorectal Liver Metastases , 2004, Annals of surgery.
[56] R. Felix,et al. Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. , 2004, Journal of vascular and interventional radiology : JVIR.
[57] L. Rubbia‐Brandt,et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] M. Gonen,et al. Second Liver Resections Are Safe and Effective Treatment for Recurrent Hepatic Metastases from Colorectal Cancer: A Bi-institutional Analysis , 2002, Annals of surgery.
[59] T. Muto,et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization , 2001, Hepatology.
[60] T. de Baère,et al. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma , 1999, The British journal of surgery.
[61] R. Reznek,et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. , 1998, British Journal of Cancer.
[62] A. Altendorf-Hofmann,et al. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history , 1990, The British journal of surgery.
[63] J. Weitz,et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.
[64] R. Parks,et al. Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC Intergroup trial 40983 ) : a randomised controlled trial , 2008 .
[65] M. Ducreux,et al. Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure , 2007, Annals of Surgical Oncology.